Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL

Brain Pathology

Volumn 8, Issue 2, 1998, Pages 263-276

  Cobbers, J M J Ludwig ^a   Wolter, Marietta ^a   Reifenberger, Julia ^a   Ring, Gudrun U ^a   Jessen, Frank ^a   An, Han Xiang ^a   Niederacher, Dieter ^a   Schmidt, Esther E ^c   Ichimura, Koichi ^c   Floeth, Frank ^a   Kirsch, Lutz ^b   Borchard, Franz ^a   Louis, David N ^d   Collins, V Peter ^c   Reifenberger, Guido ^a,e  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Evangelische Johanniter K   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Heinnch Heine Umversity   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER GENETICS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; FEMALE; GENE DELETION; GENE EXPRESSION; GENE REARRANGEMENT; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MISSENSE MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LYMPHOMA;

EID: 7144262399     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.1998.tb00152.x     Document Type: Article

References (69)

1. Adamson DJ, Thompson WD. Dawson AA, Bennett B, Haites NE (1995) p53 mutation and expression in lymphoma. Br J Cancer 72: 150-154
2. Aisenberg AC, Wilkes BM, Jacobson JO (1988) The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 71: 969-972
3. An H-X, Niederacher D, Beckmann MW, Göhring UJ, Scharl A, Picard F, van Roeyen C, Schnüren HG, Bender HG (1995) ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffinembedded breast carcinoma tissues. Int J Cancer 64: 291-297
4. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJS (1995) Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55:1351- 1354
5. Baeuerle PA, Baltimore D: NF-κB (1996) Ten years after. Cell 87:13-20
6. Bentz M, Werner CA, Dohner H, Joos S, Barth TFE, Siebert R, Schröder M, Stilgenbauer S, Fischer K, Möller P. Lichter P (1996) High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. Blood 88:1437-1444
7. Bergmann M, Blasius S, Bankfalvi A, Mellin W (1996) Primary non-Hodgkin lymphomas of the CNS - proliferation, oncoproteins, and Epstein-Barr-virus. Gen Diagn Pathol 141:235-242
8. Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N, Tassies D, Jaffe ES, Montserrat E, Rozman C, Cardesa A (1994) PRAD-1/cycIin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 84:2726-2732
9. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN (1998) Molecular genetic correlates of p16, cdk4 and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol (in press)
10. Cesarman E, Liu YF, Knowles DM (1994) The MDM2 oncogene is rarely amplified in human lymphoid tumors and does not correlate with p53gene mutation. Int J Cancer 56: 457-458
11. Chilosi M, Doglioni C, Magalini A, Inghirami G, Krampera M, Nadali G, Rahal D, Pedron S, Benedetti A, Scardoni M, Macri E, Lestani M, Menestrina F, Pizzolo G, Scarpa A (1996) p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood 88: 4012-4020
12. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM (1982) Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt's lymphoma cells. Proc Nat/ Acad Sci USA 79: 7824-7827
13. DeAngelis LM (1991) Primary central nervous system lymphoma: a new clinical challenge. Neurology 41: 619- 621
14. Eby NL, Grufferman S, Flannely CM, Schoid SCJ, Vogel FS, Burger PC (1988) Increasing incidence of primary brain lymphoma in the United States, Cancer 62: 2461-2465
15. Gaidano G, Ballerini P. Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc NatlAcad Sci USA 88: 5413-5417
16. Gilmore TD, Koedood M, Piffat KA, White DW (1996) Rel/NF-KB/lkB proteins and cancer. Oncogene 13: 1367-1378
17. Ginsberg AM, Raffeid M, Cossman J (1992) Mutations of the retinoblastoma gene in human lymphoid neoplasms. Leuk Lymphoma 7: 359-362
18. Gombart AF, Morosetti R, Miller CW, Said JW, Koeffler HP (1995) Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lyrmphomas. Blood 86: 1534-1539
19. Gong JZ, Zhou H, Hu Z, Schulman P, Vinceguerra V, Broome JD, Koduru P (1995) Absence of somatic changes in p2l gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia. Hematol Pathol 9: 171-177
20. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, van Tornout JM, Jones PA (1995) Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531-4535
21. Grant JW, Isaacson PG (1992) Primary central nervous system lymphoma. Brain Pathol 2: 97-109
22. Hangaishi A, Ogawa S, Imamura N, Miyawaki S, Miura Y, Uike N, Shimazak: C, Emi N, Takeyama K, Hirosawa S, Kamada N, Kobayashi Y, Takemoto Y, Kitani T, Toyama K, Ohtake S, Yazaki Y, Ueda R, Hirai H (1996) Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and RB genes in primary lymphoid malignancies. Blood 87: 4949-4958
23. Harris N, Jaffa E, Stem H, Banks P, Chan J, Cleary M, Delsol G, Wolf-Peeters C, Falini B, Gatter K, Grogan T, Isaacson P, Knowles D, Mason D, Müller-Hermelink H, Pileri S, Piris M, Ralfkiaer E, Warnke R (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Stood 84: 1361-1392
24. He J, Alien JR, Collms VP, Allalunis-Turner MJ, Godbout R, Day III RS, James CD (1994) CDK4 amplification is an alternative mechanism to p16gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807
25. He J, Reifenberger G, Liu L, Collins VP, James CD (1994) Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chrom Cancer 11: 91-96
26. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D, Baylin SB (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant methylation in all common human cancers. Cancer Res 55: 4525-4530
27. Hoppe-Seyler F, Bute K (1995) Molecular mechanisms of virus-induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins. J Mol Med 73: 529-538
28. Heyman M, Einhorn S (1996) Inactivation of the p15INK4B and p16INK4A genes in hematologie malignancies. Leuk Lymphoma 23: 235-245
29. Houldsworth J, Mathew S, Rao PH, Dyomina K, Louie DC, Parsa N, Offit K, Chaganti RS (1996) REL protooncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 87: 25-29
30. Hunter SB, Abbott K, Varma VA, Olson JJ, Barnett DW, James CD (1995) Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J Neuropathol Exp Neurol 54: 57-64
31. Ichikawa A, Hotta T, Takagi N, Tsushita K, Kinoshita T, Nagai H, Murakami Y, Hayashi K, Saito H (1992) Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 79: 2701-2707
32. INK4A, MTS1) and CDK4 gene have frequent mutations of the retinoblastoma gene. Oncogens 13: 1065-1072
33. Imamura J, Miyoshi I, Koeffler HP (1994) p53 in hematologic malignancies. Blood 8: 2412-2421
34. Jellinger KA, Paulus W (1995) Primary central nervous system lymphomas - new pathological developments. J Neuro-Oncol 24: 33-36
35. Joos S, Otano-Joos MI, Ziegler S, Bruderlein S, du Manoir S, Bentz M, Moller P, Lichter P (1996) Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87: 1571-1578
36. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440
37. Klein G (1989) Viral latency and transformation: The strategy of Epstein-Barr virus. Cell 58: 5-8
38. Kocialkowski S, Pezzella F, Morrison H, Jones M, Laha S, Harris AL, Mason DY, Gatter KC (1995) Mutations in the p53 gene are not limited to classic "hot spots" and are not predictive of p53 protein expression in high-grade nonHodgkin's lymphoma. Br J Haematol 89: 55-60
39. Koduru PR, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD (1995) Deletion of cyclin-dependent kinase 4 inhibitor genes p75and p16 in non-Hodgkin's lymphoma. Stood 86: 2900-2905
40. Koga H, Zhang S-J, Ichikawa T, Washiyama K, Kuroiwa T, Tanaka R, Kumanishi T (1994) Primary malignant lymphoma of the brain: demonstration of the p53 gene mutations by PCR-SSCP analysis and immunohistochemistry. Brain Tumor Pathol 11: 151-155
41. Kumanishi T, Zhang S, Ichikawa T, Endo S, Washiyaa K (1996) Primary malignant lymphoma of the brain: demonstration of frequent p16 and p15 gene deletions. Jpn J Cancer Res 87: 691-695
42. Lacy J, Summers WP, Watson M, Glazer PM, Summers WC (1987) Amplification and deregulation of MYC following Epstein-Barr virus infection of a human B-cell line. Proc Natl Acad Sci USA 84: 5838-5842
43. Lee KA, Finnegan MC, Sheridan E, Hancock BW, Goepel JR, Royds J, Goyns MH (1994) Analysis of the p53 gene, its expression and protein stabilization in non-Hodgkin's lymphomas. Ann Oncol 5 Suppl 1 : S85-88
44. Lennert K, Feller AC (1992) Histopathology of NonHodgkin's lymphomas (based on the updated Kiel classification). 2nd completely revised edition. Springer-Verlag, Berlin, Heidelberg, New York
45. Liu J, Johnson RM, Traweek ST (1993) Rearrangement of the BCL-2 gene in follicular lymphoma. Detection by PCR in both fresh and fixed tissue samples.Diagn Mol Pathol 2: 241-247
46. Lu D, Thompson JD, Gorski GK, Rice NR, Mayer MG, Yunis JJ (1991) Alterations at the REL locus in human lymphoma. Oncogens 6: 1235-1241
47. Martinez-Deigado B, Fernandez-Piqueras J, Garcia MJ, Arranz E, Gallego J, Rivas C, Robledo M, Benitez J (1997} Hypermethylation of a 5′ CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 11: 425-428
48. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baytin SB, Sidransky D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine 1: 686-692
49. Miyashita EM, Yang B, Lam KMC, Crawford DH, Thorleylawson DA (1995) A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80: 593-601
50. Morgello S (1995) Pathogenesis and classification of primary central nervous system lymphoma: an update. Brain Pathol 5: 383-393
51. Neubauer A, Neubauer B, He M, Effect P, Iglehart D, Frye RA, Liu E (1992) Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 7: 1019-1025
52. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756
53. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, Kamada N, Ohtake S, Uike N, Shimazaki C, Toyama K, Hirano M, Mizoguchi H, Kobayashi Y, Furusawa S, Saito M, Emi N, Yazaki Y, Ueda R, Hirai H (1995) Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 86: 1548-1556
54. O'Neill BR Tomlmson FH, O'Fallon JR, Scheithauer BW, Kurtin PH, O'Neill DB (1993) The continuing increase of primary central nervous system non-Hodgkin's lymphomas. Ann Neurol 34: 313 (abstract)
55. Otsudi T, Clark HM, Wellmann A. Jaffe ES, Raffeld M (1995) Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 1436-1440
56. Pinyol M, Hemandez L, Cazorla M, Balbin M, Jares P, Fernandez PL, Montserrat E, Cardesa A, Lopez-Otin C, Campo E (1997) Deletions and loss of expression of p16lNK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89: 272-280
57. Quesnel B, Preudhomme C, Oscier D, Lepelley P, Collyn-d'Hooghe M, Facon T, Zandecki M, Fenaux P (1994) Overexpression of the MDM2 gene is found in some cases of haematological malignancies. Br J Haematol 88: 415-418
58. Reifenberger G (1991) Immunhistochemie der Tumoren des Nervensystems. Springer-Verlag, Berlin, pp. 28-32
59. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP (1994) Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54: 4299-4303
60. Reifenberger J, Ring, GU, Gies U, Cobbers JMJL, Oberstraß J, An H-X, Niederacher D, Wechsler W, Reifenberger G (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp NeuroI 55: 822-831
61. Ridge SA, Dyer M, Greaves MF, Wiedemann LM (1994) Lack of MDM2 amplification in human leukaemia. Br J Haematol 86: 407-409
62. Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris ML, Arnold A (1991) PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Nati Acad Sci USA 88: 9638-9642
63. Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP (1997) Infrequent methylation of CDKN2A (MTS1/p16) and rare mutation of both CDKN2A and CDKN2B (MTS2/p15) in primary astrocytic tumours. Br J Cancer 75: 2-8
64. Schmidt EE, Ichimura K, Reifenberger G, Collins VP (1994) CDKN2(p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324
65. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert R Brodeur G, Goldstein M, Trent J: Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983, 305: 245-248
66. Segal GH, Wittwer CT, Fishleder AJ, Stoler MH, Tubbs RR, Kjeldsberg CR (1992) Identification of monoclonal Bcell populations by rapid cycle polymerase chain reaction. A practical screening method for the detection of immunoglobulin gene rearrangements. Am J Pathol 141 : 1291-1297
67. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707
68. Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D, DePmho RA (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37
69. Sherr C (1996) Cancer cell cycles. Science 274: 1672-1677